Cabio Biotech Wuhan Co Ltd (688089) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.10 Million ≈ $8.21 Million USD) by net assets (CN¥1.64 Billion ≈ $239.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688089 stock market capitalisation for the company's overall valuation and market capitalisation.

Cabio Biotech Wuhan Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Cabio Biotech Wuhan Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cabio Biotech Wuhan Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their cash flow conversion efficiency. Explore 688089 cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Central Omega Resources Tbk PT JK:DKFT	0.283x
KABE Group AB (publ.) ST:KABE-B	0.078x
ASIX Electronics TWO:3169	0.042x
ZongTai Real Estate Development Co Ltd TW:3056	-0.013x
Ohio Valley Banc Corp NASDAQ:OVBC	0.045x
OraSure Technologies Inc NASDAQ:OSUR	-0.026x
Thayer Ventures Acquisition Corporation II Class A Ordinary Shares NASDAQ:TVAI	-0.002x
Clarke Inc. TO:CKI	0.009x

Annual Cash Flow Conversion Efficiency for Cabio Biotech Wuhan Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. View Cabio Biotech Wuhan Co Ltd stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.57 Billion ≈ $229.67 Million	CN¥173.04 Million ≈ $25.32 Million	0.110x	+139.09%
2023-12-31	CN¥1.49 Billion ≈ $218.60 Million	CN¥68.89 Million ≈ $10.08 Million	0.046x	-62.75%
2022-12-31	CN¥1.43 Billion ≈ $208.53 Million	CN¥176.40 Million ≈ $25.81 Million	0.124x	+65.60%
2021-12-31	CN¥1.38 Billion ≈ $202.20 Million	CN¥103.29 Million ≈ $15.11 Million	0.075x	-32.18%
2020-12-31	CN¥1.32 Billion ≈ $193.67 Million	CN¥145.88 Million ≈ $21.35 Million	0.110x	+4.38%
2019-12-31	CN¥1.25 Billion ≈ $182.85 Million	CN¥131.95 Million ≈ $19.31 Million	0.106x	-47.66%
2018-12-31	CN¥526.20 Million ≈ $77.00 Million	CN¥106.16 Million ≈ $15.53 Million	0.202x	-6.93%
2017-12-31	CN¥464.39 Million ≈ $67.96 Million	CN¥100.66 Million ≈ $14.73 Million	0.217x	+39.56%
2016-12-31	CN¥402.60 Million ≈ $58.91 Million	CN¥62.53 Million ≈ $9.15 Million	0.155x	+23.62%
2015-12-31	CN¥354.83 Million ≈ $51.92 Million	CN¥44.58 Million ≈ $6.52 Million	0.126x	+26.32%
2014-12-31	CN¥465.90 Million ≈ $68.18 Million	CN¥46.34 Million ≈ $6.78 Million	0.099x	+7.89%
2013-12-31	CN¥428.24 Million ≈ $62.66 Million	CN¥39.48 Million ≈ $5.78 Million	0.092x	--

About Cabio Biotech Wuhan Co Ltd

SHG:688089 China Biotechnology

Market Cap

$213.04 Million

CN¥1.46 Billion CNY

Market Cap Rank

#16428 Global

#4632 in China

Share Price

CN¥8.65

Change (1 day)

-0.57%

52-Week Range

CN¥6.98 - CN¥26.42

All Time High

CN¥48.06